Search Results for MSF

Showing 1 – 10

Challenges Providing Pharmaceutical Products to Syrian Refugees By Zeina Sahloul - Published 24 May 2017

This article discusses the difficulties encountered by medical personnel working with refugees in Syria and delivering pharmaceutical products. It describes relevant regulatory policy and guidance for drug procurement and quality.

Categories: Features, Middle East, WHO, Crisis management, Drugs, Submission and registration

Tags: Syrian Refugee Crisis, Prequalification, UNHCR, Essential Medicines, MSF

Doctors Without Borders Appeals Exclusive License Granted to Sanofi for Zika Vaccine By Zachary Brennan - Published 19 May 2017

Doctors Without Borders (MSF) on Friday appealed the US Department of Defense’s decision to grant an exclusive, royalty-bearing license to Sanofi Pasteur for patents to a Zika vaccine developed with US government funds.

Categories: News, US, Biologics and biotechnology, Drugs, Research and development

Tags: Doctors Without Borders, MSF, Zika vaccine, Sanofi

Doctors Without Borders Objects to Sanofi Receiving an Exclusive License for a Zika Vaccine By Zachary Brennan - Published 24 January 2017

Doctors Without Borders (MSF) on Monday objected to the US government’s granting of an exclusive patent license to Sanofi Pasteur for a developing Zika vaccine, though Sanofi on Tuesday explained the risks of developing such a vaccine.

Categories: News, US, FDA, Biologics and biotechnology, Crisis management, Government affairs, Manufacturing

Tags: Zika, MSF, Sanofi Pasteur, Zika vaccine

Doctors Without Borders: Asian Trade Deal Could Restrict Access to Affordable Generics By Zachary Brennan - Published 21 April 2016

The Regional Comprehensive Economic Partnership (RCEP) trade agreement is kicking off another round of negotiations on Sunday in Australia and Doctors Without Borders (MSF) is raising concerns about the tougher intellectual property rights that could restrict access to affordable generic drugs for many in Indonesia, Thailand, Myanmar, Cambodia and Laos.

Categories: News, Asean, China, India, Japan, Korea, Generic drugs, Government affairs

Tags: MSF, Doctors Without Borders, KEI, HIV, TB, Indian generic drugs

MSF: Access to New TB Medicines Falters Despite Conditional Approvals By Zachary Brennan - Published 21 March 2016

Doctors without Borders (MSF) released a new report on Monday offering details on how the first new drugs in nearly half a century were conditionally approved to treat tuberculosis (TB),  though only 2% of the roughly 150,000 who could benefit from these treatments have access to them.

Categories: News, Africa, Asia, Latin America and Caribbean, EMA, WHO, Crisis management, Drugs, Government affairs, Regulatory intelligence, Submission and registration

Tags: MSF, Doctors Without Borders, TB medicines, TB drug prices, Otsuka

WHO Calls for New Antivenom Treatments as Supplies Dwindle By Zachary Brennan - Published 04 December 2015

The World Health Organization (WHO) on Friday announced it's actively searching for new snake bite treatments as supplies of the most effective antivenom treatment are due to run out in 2016. Companies can now apply, with no submission fees, to have new treatments assessed by WHO beginning in March.

Categories: News, Africa, Asia, Middle East, US, WHO, Biologics and biotechnology, Clinical, Drugs, Government affairs, Manufacturing, Regulatory intelligence

Tags: WHO, anti-venom, snake bite cures, MSF

Health Advocacy Groups Call for Changes to Priority Review Voucher Program By Michael Mezher - Published 19 November 2015

A group of health advocacy organizations are calling on the Senate Committee on Health, Education, Labor and Pensions (HELP) to tighten requirements for obtaining priority review vouchers for drugs for tropical diseases.

Categories: News, Africa, Asia, Latin America and Caribbean, US, FDA, Biologics and biotechnology, Drugs, Government affairs, Regulatory strategy, Research and development

Tags: Neglected Tropical Disease, NTD, Priority Review Voucher, PRV, Senate HELP Committee, MSF, DNDi

TPP, WTO Deals Reveal Strength of Pharma Industry’s Negotiating Power By Zachary Brennan - Published 06 November 2015

After five years of negotiations, the release of the final text of the long-awaited trade deal, known as the Trans-Pacific Partnership (TPP), on Thursday, as well as concessions made to the US in the WTO’s TRIPS (trade-related aspects of intellectual property rights) deal announced Friday both offer new insight into the strength of the pharmaceutical industry’s lobbying and negotiating powers.

Categories: News, Africa, Asia, Canada, Europe, Middle East, Oceania, US, EC, MHLW, PMDA, TGA, Drugs, Government affairs, Manufacturing, Medical Devices, Quality, Regulatory intelligence, Regulatory strategy, Reimbursement

Tags: TPP, TRIPS, WTO, least-developed countries, medicines access, KEI, MSF, trade deals, biologics exclusivity

Final TPP Agreement Draws Ire from Both Sides over Biologics Exclusivity By Zachary Brennan - Published 05 October 2015

Pharmaceutical industry groups and nonprofits expressed disappointment Monday over a compromise in the Trans-Pacific Partnership (TPP) on biologics data exclusivity.

Categories: News, Asia, Canada, Oceania, US, Biologics and biotechnology, Distribution, Government affairs, Postmarket surveillance, Regulatory intelligence, Regulatory strategy

Tags: TPP, Trans-Pacific Partnership, biologics exclusivity, BIO, PhRMA, MSF

Public Health Groups Propose Global Drug Innovation Fund By Michael Mezher - Published 13 May 2015

Two health advocacy groups, Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases initiative (DNDi) are urging public health authorities to create a global fund to tackle what they call "deadly gaps in innovation."

Categories: News, WHO, Biologics and biotechnology, Drugs, Research and development

Tags: Médecins Sans Frontières, MSF, Drugs for Neglected Diseases initiative, DNDi, Ebola, antimicrobial resistance, AMR, neglected tropical diseases, NTD